InDex Pharmaceuticals Q3 2023: Uncertain future post discontinuation of CONCLUDE - Redeye

Redeye sees a new investment case in InDex Pharmaceuticals following the discontinuation of CONCLUDE. The share trades at a substantial discount compared to its book value, which offers an interesting play on the company’s future trajectory.

Länk till analysen i sin helhet: https://www.redeye.se/research/964206/index-pharmaceuticals-q3-2023-uncertain-future-post-discontinuation-of-conclude?utm_source=finwire&utm_medium=RSS